" Dr. Madduri on the Potential Impact of CAR T-Cell Therapy in Multiple Myeloma"
Deepu Madduri, MD, assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai discusses the potential impact of CAR T-cell therapy in multiple myeloma. According to Dr. Madduri, there are several CAR T-cell products that are being explored in myeloma, most of which target BCMA. “It’ll be important to wait for the data to come out of these trials because each product would preclude exposure to another in practice.” She added, “Every year, more therapies are being approved in myeloma.”
— Deepu Madduri, MD, Assistant Professor, Medicine, Hematology and Medical Oncology, Urology, Icahn School